Grant: Idea to Innovation
University of Toronto
$124,123.00
Development of scale-up strategies for ReFilx: a novel soft tissue filler - I2I Phase 1
EF 2018-19
Résumé
Approximately 25,000 Canadian and 292,130 American women were estimated to be diagnosed with breast cancer (BC) in 2015, respectively. After several randomized controlled trials confirming the safety and efficacy of breast conserving surgery (BCS) or lumpectomy with radiation, it has replaced mastectomy as the preferred surgical treatment for BC. However, poor cosmetic outcomes and irregular soft tissue defects are commonly observed in patients that undergo BCS. In addition to impairing the patients' aesthetic appearance, soft tissue defects are a main source of psychological distress. Thus, there is a large unmet need for the correction of soft tissue defects in the breast which is currently being accommodated with limited success using other technologies that many key opinion clinicians recognize as being non-satisfactory. Using innovative biomaterials science conceived and studied over the past decade, the principle investigators (PIs) have developed ReFilx for the correction of irregular breast defects observed after lumpectomy. ReFilx constructs have a timely biodegradation rate while enabling immediate support for breast shape and form, allowing tissue ingrowth to replace the material and maintain the form. It resorbs into by-products at levels recognized by regulatory agencies as being non-toxic. Through two pilot studies using a pig model, we have identified a ReFilx formulation that satisfies the implant criteria. In this NSERC I2I application, we propose to support the commercialization of this product through development and validation of scale-up strategies for the raw materials involved in ReFilx synthesis, as well as the fabrication of the final formed constructs. This will be accomplished through two key milestones: (1) develop a scale-up strategy for the pre-polymer and (2) develop prototypes for high through-put and reproducible fabrication of ReFilx constructs. Developing and validating these processes will in turn expedite and reduce the cost of transitioning from laboratory to commercial production.*
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
531906-2018
Name nom
Santerre, Paul
Department département
Dentistry, Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
124123
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Development of scale-up strategies for ReFilx: a novel soft tissue filler - I2I Phase 1
Keyword
NSERC
Application summary
Approximately 25,000 Canadian and 292,130 American women were estimated to be diagnosed with breast cancer (BC) in 2015, respectively. After several randomized controlled trials confirming the safety and efficacy of breast conserving surgery (BCS) or lumpectomy with radiation, it has replaced mastectomy as the preferred surgical treatment for BC. However, poor cosmetic outcomes and irregular soft tissue defects are commonly observed in patients that undergo BCS. In addition to impairing the patients' aesthetic appearance, soft tissue defects are a main source of psychological distress. Thus, there is a large unmet need for the correction of soft tissue defects in the breast which is currently being accommodated with limited success using other technologies that many key opinion clinicians recognize as being non-satisfactory. Using innovative biomaterials science conceived and studied over the past decade, the principle investigators (PIs) have developed ReFilx for the correction of irregular breast defects observed after lumpectomy. ReFilx constructs have a timely biodegradation rate while enabling immediate support for breast shape and form, allowing tissue ingrowth to replace the material and maintain the form. It resorbs into by-products at levels recognized by regulatory agencies as being non-toxic. Through two pilot studies using a pig model, we have identified a ReFilx formulation that satisfies the implant criteria. In this NSERC I2I application, we propose to support the commercialization of this product through development and validation of scale-up strategies for the raw materials involved in ReFilx synthesis, as well as the fabrication of the final formed constructs. This will be accomplished through two key milestones: (1) develop a scale-up strategy for the pre-polymer and (2) develop prototypes for high through-put and reproducible fabrication of ReFilx constructs. Developing and validating these processes will in turn expedite and reduce the cost of transitioning from laboratory to commercial production.*